Changes to RFA-TR-17-003: Limited Competition for NIH-Industry Program: Discovering Pediatric New Therapeutic Uses for Existing Molecules (UG3/UH3)

Notice Number: NOT-TR-17-013

Key Dates
Release Date:   March 23, 2017

Related Announcements
RFA-TR-17-003

Issued by
National Center for Advancing Translational Sciences (NCATS)

Purpose

The purpose of this notice is change the Award Budget allocations for both the UG3 and the UH3 for the RFA-TR-17-003: Limited Competition for NIH-Industry Program: Discovering Pediatric New Therapeutic Uses for Existing Molecules (UG3/UH3).

Section II. Awards Information

Award Budget

Currently reads:

Application budgets need to reflect the actual needs of the proposed project but must not exceed $300,000 in direct costs for each year of the UG3 phase and $500,000 (direct costs) for each year of the UH3 phase.

Modified to read:

Application budgets need to reflect the actual needs of the proposed project but must not exceed $1,750,000 in direct costs for each year of the UG3 phase and $3,000,000 (direct costs) for each year of the UH3 phase.

All other aspect of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Bobbie Ann Austin, Ph.D.
National Center for Advancing Translational Sciences (NCATS)
Telephone: 301-435-0824
Email: NewTherapeuticUses@mail.nih.gov